BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23934050)

  • 1. [Biosimilars : Current state of the build up to series production].
    Aringer M; Dörner T
    Z Rheumatol; 2013 Nov; 72(9):873-7. PubMed ID: 23934050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
    Dranitsaris G; Amir E; Dorward K
    Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biosimilars versus original biologics. Similarities and differences from development to approval].
    Windisch J
    Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic facts about biosimilars.
    Nowicki M
    Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
    Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
    MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.